Preclinical efficacy of copanlisib in cetuximab sensitive and resistant tumors of HNSCC.

6031Background: Copanlisib is a highly selective, pan-class I PI3K inhibitor with preferential activity against the p110α and p110δ isoforms that lead to downregulation of PI3K signaling. Copanlisi...